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1 Introduction 
1.1 Lung development 
The lungs are the organs necessary for breathing, although initially appear to be 
unnecessary for intrauterine existence. Nevertheless, the lungs are programmed to 
function immediately after birth. During fetal development, the branching and growth 
of the lungs are under the direction of the mesenchyme. This characteristic is also 
found in kidney, where epithelial-mesenchymal interaction is important for the 
normal development of the lungs (Koshida and Hirai 1997).   
Lung development is a lengthy process passing through different stages until reaches 
maturation. Development starts in the third week of the embryonic stage and it is 
approximately completed at 2-3 years of age where alveoli and total lung structure are 
fully matured. Over the past years, there is strong evidence that the alveoli number 
and lung surface area continue increasing until adulthood (Hislop 2002).  
 
1.2 Phases of lung development 
In humans, the respiratory tract passages are divided into 23 division points or 
generations (Fig 1-1). At every generation, one airway is divided into two smaller 
airways. The human respiratory tree consists on average of 23 generations, while the 
respiratory tree of the mouse has up to 13 generations. The last generations include 
the respiratory bronchioles, alveolar ducts and alveoli which are specialized structures 
for proper gas exchange (Kitaoka et al. 1996). Based on histological characteristics, 
there are five developmental stages that have been defined: the embryonic, the 
pseudoglandular, the canalicular, the saccular and the alveolar stage. The early stages 
are characterized by branching morphogenesis, while the later stages are characterized 
by vascularization and the formation of thin air-blood interfaces responsible for gas 
exchange (Boucher et al. 2009). During the pseudoglandular stage, the epithelial tube 
undergoes branching, generating the respiratory part to the level of distal bronchioles. 
During the canalicular stage, the distal airway bronchioles are formed with a 
significant proximal to epithelial differentiation. This is the stage where mesenchymal 
cells begin to develop into fibroblasts, lipofibroblasts and myofibroblasts (Goldin and 
Wessells 1979). 
  
10 
 
 
 
 
 
Figure 1-1 Lung development and respiratory tract generations .  
According to their function, the respiratory tract passages are divided into conducting 
and respiratory zones. Conducting zones consist of 16 generations including bronchi, 
bronchioles and terminal bronchioles. The respiratory zone consists of seven  
generations including respiratory bronchioles, alveolar ducts and alveolar sacculi  
(Weibel 1963).  
 
By the end of canalicular stage (Fig 1-2), between weeks 16 and 25, 
respiration is possible, although the survival rates of newborns delivered at this stage 
are low. Between week 25 and birth, during the saccular stage, there is a massive 
expansion of airspaces and pneumocytes start producing surfactant. At this stage, 
newborns have a much higher probability of survival. However, even at this stage, 
respiratory support for the newborns is necessary. The positive pressure ventilation 
with a high oxygen gas can lead to chronic lung injury and is a major factor for the 
development of bronchopulmonary dysplasia (BPD) (Coalson 2006).  
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Figure 1-2 Overview of the stages in normal lung development .  
There is a significant  expansion of the lung in the saccular stage, and a  generation of 
an increasing number of alveoli of a smaller size, between the saccular phase and  the 
mature lung (Boucher et al. 2009).  
 
During the final stage of lung development, the process of septation takes 
place. This is the process by which new alveolar sacs are generated, and can be seen 
in detail in Figure 1-3, where the wall of an existing alveolus gives rise to a new 
septum, which then extends and grows to form the wall of a new alveolus. The 
alveolarization stage leads to a honeycomb appearance accompanied by a significant 
increase in gas exchange surface area.  After septation has been completed, the final 
phase of late lung development is the consolidation of the capillary layers, in the stage 
of “microvascular maturation” (Fig 1-3 D). In humans the alveolar stage starts during 
the fetal period but in rodents alveolarization is predominantly a post-natal (P) event. 
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Figure 1-3 Structural mechanism for late lung alveolarization.  
The points of formation of new “secondary septa” are indicated by a blue arrow. Panels 
(B) and (C) illustrate how the newly formed secondary septa lead to the formation of  a 
new alveolus (Schittny et al. 2008).  
 
 
1.3    MicroRNAs and lung development 
MicroRNAs belong to a large group of non-coding small RNAs and are 20-22 
nucleotides (nt) in length. MicroRNAs were first described in 1993 as negative 
regulators in Caenorhabditis elegans, with Lin-14 being the first described 
microRNA gene, influencing the timing of the larva to adult switch. Since then, 
thousands of microRNAs have been identified that are highly conserved across 
species and have been established as major regulators of gene expression. Studies up 
to this point have demonstrated that one third of human genes are regulated by 
microRNAs. These genes are mainly involved in developmental timing, cellular 
differentiation, immune regulation, cell cycle and apoptosis (Fineberg et al. 2009, 
Gangaraju and Lin 2009, Lewis et al. , Mattes et al. 2008). 
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1.3.1 Biogenesis and function of microRNAs 
In the nucleus, a primary microRNA (pri-miR) is transcribed from microRNA 
genes and is synthesized by RNA polymerase II (Cai et al. 2004, Vicencio et al. 
2004). Expression of different microRNAs is under the control of transcription 
factors, for example c-Myc or p53 (He et al. 2007, O'Donnell et al. 2005), or depends 
on the methylation of microRNA promoters (Lujambio et al. 2008, Saito et al. 2006). 
Additionally, it has been shown that each microRNA located in the same genomic 
cluster can be transcribed and regulated independently (Song and Wang 2008).  The 
primary microRNA is processed by the RNase III enzyme Drosha and the DGCR8 
(DiGeorge critical region 8) protein, leading to a smaller sequence (~ 70 nt) defined 
as a precursor microRNA (pre-miR).  
After the completion of the process in the nucleus, the pre-miR is transferred 
into the cytoplasm by Exportin-5 (XPO5) in complex with Ran-GTP (Yi et al. 2003). 
Knockdown of Exportin-5 leads to lower abundance of mature microRNA sequences, 
indicating that Exportin-5 protects pre-miRs against nuclear digestion (Lund et al. 
2004, Yi et al. 2003).   
   In the cytoplasm, the pre-miR is cleaved by another RNase III enzyme (Dicer) 
and generates roughly a 22-nt double stranded miR duplex molecule. Deletion of 
Dicer decreases the production of mature miRs (Grishok et al. 2001, Hutvagner et al. 
2001). This miR duplex is then separated into two single strands, the mature strand 
(miR) and the passenger strand (miR*). The mature microRNA is incorporated into 
the RNA induced silencing complex (RISC) as a template for the target mRNA and 
the passenger microRNA is degraded (Fig 1-4). The RNA induced silencing complex 
is a large protein complex and includes the argonaute protein (AGO), the 
transactivating response RNA binding protein (TRBR) and the fragile X mental 
retardation protein (FMRP1). The Argonaute 2 is an isoform of the AGO protein and 
it is the one responsible for the cleavage of the target mRNA. The mature sequence of 
the microRNAs binds to the 3 prime untranslated region (UTR) of the target mRNA 
and inhibits the gene expression by two different mechanisms; either by mRNA 
degradation or by translational repression. RISC inhibits translation by recruiting 
factor eIF6, causing detachment of the 80S ribosomal complex (Iwasaki et al. 2009). 
Deadenylation of mRNA is another mechanism triggered by AGO protein isoforms 
and leads to degradation of the target mRNA.  
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Figure 1-4 The canonical pathway of microRNA processing has been associated 
with all mammalian microRNAs .  
 This pathway includes the generation of  a pri-miR by RNA polymerase II and the 
cleavage of the pri -miR by the Drosha-DGCR8 complex in the nucleus. The resulting 
sequence (pre-miR) is exported to the cytoplasm by Exportin -5. In the cytoplasm, the 
enzyme Dicer cleaves the pre-miR sequence to a mature form. The mature sequence of 
the microRNA is loaded with Argonaute proteins, and the complex targets mRNAs 
through cleavage,  translational repression or deadenylation. The passenger  strand is 
degraded and it is not funct ional (Winter et al. 2009). GTP, guanine triphosphate; Ran, 
RA-related nuclear protein.   
 
1.3.2 MicroRNAs in the lung 
There is an array of studies that have profiled the expression of several 
microRNAs at various stages of lung development. One of the first studies that 
demonstrated the implication of microRNAs in lung development was conducted by 
Harris et al. (Harris et al. 2006). A conditional knock-out mouse ablated Dicer after 
the initiation of lung branching. The mutant lines demonstrated an extensive arrest in 
branching with an abnormal growth of the epithelial tube. Recently, Dong et al. 
performed a systematic clustering and expression profiling of microRNAs, target 
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mRNAs and proteins at different stages of lung development (Dong et al. 2012). 
According to the study, most of the microRNAs that increased their expression levels, 
correlated with a down-regulation of their predicted target mRNAs. In other cases, 
over half of the proteins that were analyzed, a down regulation occurred 
independently of changes in mRNA levels. These findings support the hypothesis that 
the inhibition of translation is an important mechanism of microRNAs  (Dong et al. 
2010). There are not many studies addressing the function of microRNAs in later 
stages of development. Most of the studies focus on embryonic development; for 
example Carraro et al.  have proposed a role for the  miR-17~92 cluster during early 
lung development, through regulation of the fibroblast growth factor (FGF) and the 
effects on E-cadherin expression (Carraro et al. 2009). In that study it was 
demonstrated that a down- regulation of miR-17, miR-20a and miR-106b disrupts 
embryonic lung branching through E-cadherin redistribution. The E-cadherin 
expression and distribution are important for epithelial cell organization during lung 
branching. It has also been demonstrated that miR-17 negatively regulates FGF10 
signaling by targeting Mapk14 and Stat3 (Liu Yuru et al. 2008).  
  For late lung development, and specifically for the alveolar stage, there are 
only two studies that have investigated the expression levels of microRNAs. Williams 
et al. analyzed the differential expression of microRNAs between post-natal (P) day 1 
and P14 in mice and humans (Williams et al. 2007). Microarray profiling of mouse 
lungs revealed an up-regulation of 14 microRNAs in neonatal lungs and an up-
regulation of 30 microRNAs in adult tissues. Few of the most highly regulated 
microRNAs were miR-335, miR-154, miR-370 and miR-337. MicroRNA expression 
levels were similar in mouse and human lungs, suggesting that microRNA expression 
is evolutionary conserved among species during late lung development (Williams et 
al. 2007). In the second study, Bhaskaran et al. demonstrated that miR-127 was the 
highest expressed microRNA just before and after birth, during the alveolar stage in 
rats. It was observed that miR-127 expression has a tendency to shift from 
mesenchymal to epithelial cells in the developing lung. That suggests a role for this 
microRNA in cellular processes such as cell differentiation (Bhaskaran et al. 2009).  
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1.4 Bronchopulmonary dysplasia  
Bronchopulmonary dysplasia is also referred as neonatal chronic lung disease 
and is characterized as a chronic pulmonary disorder of prematurely born infants with 
a very low birth weight. Bronchopulmonary dysplasia was first described in 1967 by 
W.H. Northway and colleagues as a severe complication of preterm birth (Northway 
et al. 1967), and since then it has been noted as a major cause of morbidity in neonatal 
intensive care units. The disease has a varied degree of severity including recurrent 
pulmonary infections, impaired neurological development and pulmonary 
hypertension. There are two types of BPD that have been described, the ‘classic’ or 
‘old’ has been substituted by the milder ‘new’ BPD. The improved perinatal care has 
led to this transformation that also reduced the morbidity rates. The ‘old’ BPD was 
characterized by extensive inflammatory changes and the ‘new’ by a decreased degree 
of secondary alveolar septation and an arrest of late lung development. According to 
Northway, there are 4 stages of BPD, mainly defined by clinical characteristics. Stage 
I (usually 2-3 days) noted as respiratory distress syndrome (RDS); stage II (4-10 days) 
noted as regeneration; stage III (11-20 days) noted as transition to chronic disease and 
stage IV (more than one month) noted as a chronic lung disease. Later, Bancalari et 
al.   attempted to define BPD as a disorder among infants who received supplemental 
oxygen at 28 days postnatal (Bancalari and Claure 2006). In 2000, the National 
Institute of Child Health and Human Development (NICHD) redefined BPD (Fig 1-
5): BPD was for the first time characterized by the severity of the disease. The disease 
was defined and categorized into mild, moderate and severe BPD (Table 1-1). 
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Figure 1-5: Severity of BPD, based on the National Institutes of Health  2000 
conference definition .  
9575 infants were categorized according to severity of BPD ; sixty eight percent of 
these infants had BPD. Severity of BPD decreased as gestational age increased  (Jobe 
2011). 
 
In 2004, Walsh et al. developed a physiological test that established the need 
for supplemental oxygenation (Walsh et al. 2004). According to the algorithm for the 
physiological test, infants receiving inspired oxygen concentration with a fraction of 
>0.3 are categorized as having BPD, and infants with a fraction of <0.3 must undergo 
an oxygen challenge test to determine if they develop BPD. Bronchopulmonary 
dysplasia is a disease with a multifactorial causality, and the factors include 
prematurity, gender, genetic predisposition, mechanical ventilation and postnatal 
infection. 
 
Table 1-1 Diagnostic criteria and categorization of the severity of BPD   (Jobe 
2011). wk, week; PMA, postmenstrual age.        
<32 wk Gestational age >32 wk Gestational age Diagnosis 
Breathing room air at 36 wk PMA or 
discharge, whichever comes first 
Breathing room air by 56 days postnatal age 
or discharge, whichever comes first 
Mild 
Need for <30% O2 at 36 wk PMA or 
discharge, whichever comes first 
Need for  <30% O2 at 56 days postnatal age 
or discharge, whichever comes first 
Moderate 
Need for >30% O2 , positive pressure, or 
both at 35 wk PMA or discharge, 
whichever comes first 
Need for >30% O2 , positive pressure, or both 
at 56 days postnatal age or discharge, 
whichever comes first 
Severe 
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1.4.1 Epidemiology 
The improved perinatal care reduced the respiratory clinical incidents and the 
characterization of BPD has changed throughout the years. The diagnostic markers of 
the disease are subjects in multiple studies making it possible for the future to prevent 
and possibly treat the disease.  
A study in 2001 noted that 23% of newborns with a birth weight below 1500 g are 
oxygen dependent at 36 weeks  (Lemons et al. 2001). In 2003, another study noted 
that 53% of infants born before 28 weeks of gestational age were oxygen-dependent 
at 36 weeks (Schreiber et al. 2003). 
As a long-term outcome, children with BPD have higher rates of educational 
and behavioral impairments and also reduced lung function throughout childhood. 
Short et al. supported that BPD has long term effects on cognitive and academic 
achievement. Infants with a very low birth weight (VLBW) have motor skill 
impairment and linguistic developmental delay compared to healthy controls (Short et 
al. 2003). Respiratory symptoms in patients with BPD persist until adulthood and 
these subjects have a higher chance of developing chronic obstructive pulmonary 
disease (COPD) (Short et al. 2003).  
 
1.5 TGF- signaling pathway 
Transforming growth factor β is a key growth factor conserved amongst 
vertebrates, regulating embryonic development and organogenesis, wound repair, cell 
proliferation, apoptosis and cell differentiation. TGF-β is secreted in an inactive form 
and deposited into the extracellular matrix (ECM) where is coupled to latent TGF-β 
binding proteins. The activated form of TGF-β can be recognized by TGF-β receptors 
1 (TGFRI) and 2 (TGFRII). Transforming growth factor receptor 1 includes activin 
receptor like kinase ALK1 and ALK5, TGF-β receptor 2 belongs to the TGFRII 
family and betaglycan and endoglin represent type III receptors. Upon ligand binding, 
receptor I and II undergo heterodimerization in a series of activation events. 
Specifically, the ligand is recognized by the TGF-β receptor 2 and initiates the 
phosphorylation of TGF-β receptor 1, resulting in the association of both molecules. 
Subsequently, receptor 1 phosphorylates the SMAD2 protein (homologs of the 
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Drosophila protein mothers against decapentaplegic) which is docked to the receptor 
complex (Fig 1-6). During the canonical TGF-β signaling, activated SMAD2 and 
SMAD3 proteins form a complex with SMAD4 and translocate into the nucleus and 
act as transcription factors. The SMAD2 and SMAD3, which are also referred as 
receptor SMADs (R-SMADs), share similar structures with the presence of MH1 and 
MH2 domains on the N and C-terminus respectively. The MH1 region is responsible 
for DNA binding while the MH2 region regulates protein-protein interactions. The 
TGF-β superfamily is not limited only to SMAD pathway but it can also mediate 
signaling through non-SMAD pathways, specifically through mitogen activated 
protein kinase (MAPK) pathways, including p38 and Jun N-terminal kinase (JNK) 
(Miyazono et al. 2005). Once the pathway is activated, there is a negative feedback 
mechanism caused by another group of SMAD proteins and can regulate the 
signaling. The proteins responsible for this inhibitory feedback are named inhibitory 
SMADs (I-SMADs) and consist of SMAD6 and SMAD7. The I-SMADs lack the 
MH1 domain and are both stimulated by TGF-β and BMP ligands; I-SMADs compete 
with R-SMADs following an association with the respective type I receptors and 
negatively regulate TGF-β family signals (Imamura et al. 1997, Nakao et al. 1997). 
As a matter of fact, the inhibitory SMADs recruit the E3 ubiquitin ligases, SMAD 
ubiquitin-related factor-1 (SMURF1) and SMAD ubiquitin-related factor-2 
(SMURF2), which are able to ubiquitinate the SMADs and the TGFRI, leading to 
protein degradation and consequently to inhibition of the signaling. The TGF-β 
superfamily also stimulates the production of secreted protein acidic rich in cysteine 
(SPARC), which enhances TGF-β signaling; it also stimulates the production of 
cystatin C that inhibits TGF-β signaling (Sokol and Schiemann 2004, Sokol et al. 
2005).  
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Figure 1-6  Representation of  the TGF-β signaling pathway .   
Extracellular TGF-β family ligands bind directly to  the type II receptor which form 
heterodimers with the type I receptor. This reaction activates the receptor  
serine/threonine kinase activity to phosphor ylate Smad2/3 complex. The 
phosphorylation of the receptor activated  the Smad2/3 complex leads to formation of 
heterodimers with partner proteins such as Smad4. Finally , the entire complex 
translocates to nucleus where  activates or inhibits the transcription of target genes 
(Massague 2012). TGF-β, transforming growth factor ; BMP, bone morphogenic 
protein; Smad, homologs of the Drosophila  protein mothers against decapentaplegic;  
 
Concerning the inhibitory proteins, which form a part of the current study, it 
has been reported over the last decade that a balanced expression of SMAD7 levels is 
necessary for homeostasis during embryonic development and for proper function of 
many organs (Zhu et al. 2011). For example, deregulation of SMAD7 can cause major 
developmental defects in cardiovascular morphogenesis and lung branching (Zhu et 
al. 2011). In terms of potential therapy against fibrosis and the excessive production 
of ECM components caused by TGF-β, an overexpression of SMAD7 might lead to a 
promising therapy (Briones-Orta et al. 2011). In a recent study, SMAD7 has been 
characterized as a microRNA target; activation of TGF-β signaling pathway promotes 
the expression of the miR-21 in vascular smooth muscle cells and in lung fibroblasts 
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(Davis et al. 2008, Liu G. et al. 2010). An up-regulation of miR-21 expression 
decreased SMAD7 expression levels, where antagomirs against miR-21 increased 
SMAD7 expression in the lung fibroblasts. This finding suggests an involvement of a 
microRNA in the TGF-β signaling pathway (Liu G. et al. 2010).   
 
1.5.1 Hyperoxia and TGF-β signaling 
It has been reported that injury to the developing lung caused by hyperoxia 
can disrupt major pathways, such as TGF-β signaling, leading to developmental arrest 
(Alejandre-Alcazar et al. 2007, Kotecha et al. 1995, Lecart et al. 2000).  Higher levels 
of TGF-β ligands have been observed in neonates with BPD undergoing oxygen 
therapy and in animal models with lung injury (Buckley and Warburton 2002). Also, 
exposure of alveolar type II (ATII) cells to 95% O2 promoted the association of 
Smad2/3/4 complexes with DNA (Nabeyrat et al. 2001), indicating that hyperoxia up-
regulates TGF-β signaling. Other studies have reported that up-regulation of TGF-β in 
rodents result in pulmonary changes that are similar to those observed in BPD 
(Gauldie et al. 2003, Vicencio et al. 2004). In 2007, Nakanishi et al. reported that 
TGF-β neutralizing antibodies attenuated the increase in nuclear phosphorylation of 
SMAD2, a major indicator of TGF-β signaling activation. The neutralization of the 
overexpression of TGF-β signaling improved alveolarization, ECM assembly and 
vascular development in the injured lung (Nakanishi et al. 2007). At a cellular level, 
hyperoxia can induce metabolic changes and can play a key role in the 
transdifferentiation of lung fibroblasts to myofibroblasts. This transdifferentiation can 
occur spontaneously but it is noted that is accelerated by exposure to high oxygen 
concentration (Boros et al. 2002). Specifically, the immature lung lipofibroblasts 
when exposed to hyperoxia differentiate to a phenotype with contractile elements and 
a high proliferating potential, referred as myofibroblasts. Myofibroblasts belong to the 
family of fibroblasts, and highly express α-smooth muscle actin (α-SMA) among 
other contractile elements, and have been identified as key mediators of idiopathic 
pulmonary fibrosis (IPF) and other profibrotic conditions (Fallowfield 2011, Hardie et 
al. 2009, Makinde et al. 2007). The fibroblast phenotype with such properties is TGF-
β dependent and arises after chronic epithelial injury or inflammation, two major 
characteristics of BPD. Bozyk et al, reported that in BPD, alveolar septa are thickened 
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with collagen and α-SMA produced by myofibroblasts. Periostin is another molecule 
expressed by myofibroblasts and was co-localized with α-SMA in infants dying from 
BPD (Bozyk et al. 2012). However, another study reported that a profound deficiency 
in alveolar myofibroblasts and elastic fibers resulted in the absence of secondary septa 
and definitive alveoli. That was mainly due to the fact that myofibroblasts failed to 
migrate from the proximal sites to the peripheral sites of the lung where elastin 
deposition occurs (Bourbon et al. 2005). To date, there is no study referring to the 
balance of the number of “accumulated” myofibroblasts in healthy conditions or in 
disease. Thus, myofibroblasts are essential, as a unique source of connective tissue 
material during secondary septation but are also involved in fibrotic processes in the 
reparative mechanisms in response to lung injury.    
 
1.5.2 The role of TGF-  in lung development and BPD 
The TGF-β signaling pathway appears to be responsible for a large part of the 
regulatory balance in lung development (Alejandre-Alcazar et al. 2008). All isoforms 
of TGF-β, TGF-β1, TGF-β2 and TGF-β3 are expressed early in pulmonary 
development along with the members of SMAD protein family (Schmid et al. 1991).  
It has been shown that down regulation of TGF-β receptor 2 and SMAD2/3/4 is 
associated with increased branching morphogenesis in mouse lung explants (Zhao et 
al. 1998). However, overexpression of TGF-β1 in the distal pulmonary epithelium led 
to an arrest in development (Wu et al. 2007). These findings indicate the negative 
influence that TGF-β1 has on lung branching and that the balance of the TGF-β 
signaling is important for homeostasis (Zhou et al. 1996). In alveolar epithelial cells, 
TGF-β1 inhibits proliferation, induces epithelial-to-mesenchymal transition (EMT) 
and apoptosis (Kasai et al. 2005). During late lung development, chronic exposure to 
hyperoxia severely decreases alveolarization and vasculogenesis (Nakanishi et al. 
2007). This finding is supported by the evidence that the level of TGF-β1 observed in 
tracheal effluents of premature newborns appears to be elevated in the ones that 
develop BPD (Kotecha and Kotecha 2012). Neptune et al showed that mice deficient 
in fibrillin-1 have increased TGF-β signaling and reduced alveolarization (Neptune et 
al. 2003). Additionally, data suggest that injury of the lung during the saccular stage 
causes the formation of dysmorphic blood vessels; the expression levels of PECAM-
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1, a protein abundant in endothelial cells, has been observed to be abnormally 
distributed in the septal walls of infants that have died from BPD (Bhatt et al. 2001). 
It has been reported that TGF-β decreases PECAM-1 expression in the lungs of 
developing mice (Zeng et al. 2001). Additional studies on the long-term effect of 
TGF-β signaling and the possible inhibition will further develop approaches in the 
modulation of pulmonary injury. 
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2 Hypothesis and aims of the study 
In the lung, tissue-specific deletion of Dicer, the enzyme responsible for 
producing active microRNAs, results in branching arrest and revealed the importance 
of microRNAs for epithelial morphogenesis (Harris et al. 2006). The deletion of 
microRNAs miR-17 and miR-92, which together form a cluster in mice, exhibited 
early embryonic or post-natal lethality, characterized by severely hypoplastic lungs 
(Carraro et al. 2009).  
Given the emerging importance of microRNA in organ development, 
including the early development of the lung, it has been hypothesized that 
microRNAs also have a functional role in late lung development, especially during 
secondary septation. To investigate the above hypothesis, the following aims were 
explored.  
 
The specific aims of this study were: 
 
1. Screening of microRNA expression during normal late lung development; 
 
2. Screening of microRNA expression during pathological late lung 
development; 
 
3. Investigate whether microRNAs have a functional role during pathological 
late lung development; 
 
4. Associate specific microRNAs with candidate mRNA targets; 
 
5. To test whether restoration of microRNA levels can be accomplished in vivo; 
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3 Materials and methods 
3.1 Materials 
3.1.1 Technical equipment 
 
Equipment Manufacturer 
Bacterial culture incubator Heraeus, Germany 
Cell culture incubator HERAcell 150i Thermo scientific, USA  
Cell culture working bench Thermo Scientific, USA 
Centro LB microplate luminometer Berthold, Germany 
Countess cell counter Invitrogen, UK 
Developing machine X omat 2000 Kodak, USA 
Electrophoresis chambers Bio-Rad, USA 
Gel blotting paper Bioscience, Germany 
Inolab pH meter WTW, Germany 
IsoplateB&W 96-well plate PerkinElmer, USA 
Light microscope Leica, Germany 
MicroAmp 8-tube strip Applied Biosysystems, USA 
Microcentrifuge tubes:0.5, 1.5, 2ml Eppendorf, Germany 
Mini shaker VWR, USA 
Mini Trans-Blot western blot chambers Bio-Rad, USA 
Minispin centrifuge Eppendorf, Germany 
MS-100 thermo shaker Universal Labortechnik, Germany 
Nanodrop ND 1000 Peqlab, Germany 
Nanozoomer XR C12000 Hamamatsu, Japan 
Nylon net filters, 20m Millipore, USA 
PeqSTAR 96 universal gardient  
thermocycler 
Peqlab, USA 
Petri dishes Greiner Bio-one, Germany 
Pipetboy Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000 Gilson, France 
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3.1.2 Chemicals and reagents 
 
2-Propanol Merck, Germany 
Agarose Promega, Germany 
Ammonium chloride Sigma-Aldrich, Germany 
Ammonium persulfate Promega, Germany 
Ampicillin sodium salt Sigma-Aldrich, Germany 
Antagomirs-LNA Exiqon, Denmark 
Bovine serum albumin Sigma-Aldrich, Germany 
CompleteProtease inhibitor Roche, Germany 
dNTP mix Promega, USA 
DTT Promega, USA 
Dual-Luciferase reporter assay system Promega, USA 
Dulbecco’s modified Eagle’s medium Gibco BRL, Germany 
Dulbecco’s modified Eagle’s medium, 
high glucose 
Gibco BRL, Germany 
Dulbecco’s phosphate buffered saline PAA Laboratories, Austria 
Pipetman filter tips:10, 20, 100, 200, 
1000 l 
Greiner Bio-One, Germany 
Refrigerated microcentrifuge CT15RE VWR, USA 
Serological pipettes: 5, 10, 25, 
 50 ml 
Falcon, USA 
StepOne Plus Real-Time PCR system Applied Biosystems, USA 
Test tubes: 15, 50 ml Greiner Bio-One, Germany 
Tissue culture dish 100 mm Greiner Bio-One, Germany 
Tissue culture flask 250 ml Greiner Bio-One, Germany 
Tissue culture plates: 6-, 12-, 48- and 96-
well 
Greiner Bio-One, Germany 
Tranfer membrane nitrocellulose Bio-Rad, USA 
  
27 
 
Dulbecco’s phosphate buffered saline, 1× PAA Laboratories, Austria 
EDTA Sigma-Aldrich, Germany 
EGTA Sigma-Aldrich, Germany 
Ethanol 70% SAV-LP, Germany 
Ethanol 99% J.T. Baker Mallinckrodt Baker B.V., The 
Netherlands 
Ethanol absolute Riedel de Hän, Germany 
Ethidium bromide Promega, USA 
Fetal calf serum PAA Laboratories, Austria 
Giemsa’s azur eosin methylene blue 
solution 
Merck, Germany 
Glycerol Carl Roth, Germany 
Glycine Carl Roth, Germany 
Glycol methacrylate Heareus Kulzer, Germany 
Hank’s balanced salt solution PAA Laboratories, Austria 
HEPES PAA Laboratories, Austria 
Hydrochloric acid Sigma-Aldrich, Germany 
Isoflurane CP-Pharma, Germany 
Lipofectamine 2000 Invitrogen, UK 
Luria-Bertani medium Invitrogen, UK 
Magnesium chloride Sigma-Aldrich, Germany 
Magnesium chloride, 25mM Applied Biosystems, USA 
May-Gruenwald’s  
eosin-methylene blue solution 
Merck, Germany 
-mercaptoethanol Sigma-Aldrich, Germany 
Methanol Fluka, Germany 
MuLV reverse transcriptase Applied Biosystems, USA 
Non-fat dry milk Carl Roth, Germany 
Nuclease free water Ambion, USA 
Opti-MEM medium Gibco BRL, Germany 
Osmium tetroxide Sigma-Aldrich, Germany 
Passive lysis buffer Promega, USA 
PCR buffer II, 10× Applied Biosystems, USA 
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Penicillin/streptomycin PAA Laboratories, Austria 
Potassium bicarbonate Sigma-Aldrich, USA 
PrecisionPlus Proteinstandards Bio-Rad, USA 
Proteinase K Promega, USA 
QIAquick gel extraction kit Qiagen, The Netherlands 
QIAquick PCR purification kit Qiagen, The Netherlands 
Quick startBradford dye reagent  Bio-Rad, USA 
Random hexamers Applied Biosystems, USA 
RIPA buffer Thermo Scientific, USA 
RNase inhibitor Applied Biosystems, USA 
Rotiphorese Gel  
30 acrylamide/bisacrylamide mix 
Carl Roth, Germany 
SDS, 10% solution Promega, USA 
SDS, powder Carl Roth, Germany 
Select agar Sigma-Aldrich, Germany 
Sodium acetate Sigma-Aldrich, Germany 
Sodium cacodylate trihydrate Sigma-Aldrich, Germany 
Sodium chloride Merck, Germany 
Sodium orthovanadate Sigma-Aldrich, Germany 
Sodium phosphate Sigma-Aldrich, Germany 
Sodium sulfate Merck, Germany 
Supersignal West 
Femto chemiluminescent substrate 
Thermo scientific, USA 
TEMED Bio-Rad, USA 
TGF-1 R&D Systems, USA 
Tris Carl Roth, Germany 
Triton X-100 Promega, USA 
TRIzol reagent Ambion, USA 
Trypan blue Fluka, Germany 
TurboFect reagent Thermo scientific, USA 
Tween 20 Sigma-Aldrich, Germany 
Uranyl acetate Serva, France 
 
  
29 
 
3.1.3 Cell lines 
NIH/3T3 fibroblast cell line, Invitrogen, UK 
 
3.2 Methods 
 
3.2.1 NIH/3T3 cell culture 
NIH/3T3 mouse embryonic cell line was cultured in culture flasks using 
Dulbecco’s modified Eagle’s medium (DMEM) containing supplemental 10% fetal 
bovine serum (FBS), at 37 ºC with 5% CO2 and 95% humidity. When cells reached 
70-80% confluency, were subcultured (after being washed using phosphate-buffered 
saline – PBS) followed by incubation with 3 ml Trypsin-EDTA for 5 min at 37 ºC. 
The next step was to inhibit the activity of the enzyme by using 7 ml of culture 
medium with FBS. The cell suspension was diluted 1:3 in medium plus the FBS and it 
was passed into a new cell culture flask.  
 
3.2.2 Culture of primary fibroblasts 
Primary mouse lung fibroblasts were isolated using a modified protocol 
published by Seluanov and collaborators (Seluanov et al. 2010). Female adult 
C57BL/6J mice were sacrificed using isofluorane. The anterior abdomen was opened 
by midline incision using with sterile scissors. The lungs were perfused using PBS, 
after puncturing the left atrium and injected through the right ventricle. The lungs 
were removed, were transferred to a cell culture dish containing 10 ml of cold 
isolation medium and were cut into small pieces using sterile scissors. The pieces 
were transferred to a 50 ml Falcon containing pre-warmed 2 mg/ml collagenase type 
I, and left incubating at 37 ºC for 45 min. The resulting suspension was filtered 
through a 40-µm cell strainer. The filtrate was then centrifuged at 400 g for 8 min at 4 
ºC and the pellet was re-suspended in 10 ml of growth medium. The solution was 
centrifuged again at 400 g for 8 min at 4 ºC (washing). The pellet was suspended in 
10 ml of growth medium, and the suspension was added to a new culture flask.  
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Isolation medium Growth medium 
High glucose DMEM High glucose DMEM 
20% FBS  10% FBS 
1% penicillin/streptomycin 1% penicillin/streptomycin 
 
3.2.2.1 Treatment of primary fibroblasts 
Primary lung fibroblasts were seeded on a 6-well plate at a density of 106 
cells/well. Each well was treated with 5 ng/ml of TGF-β1 for 6 or 24 h. The use of 
SB431542 (10 nM) inhibited the TGF-β signaling; the inhibitor was added to the 
media at the same time as the transfection reagents.  
 
3.2.2.2 Transfection of microRNA mimics and short interfering 
RNA 
The TurboFect transfection reagent (Thermo Scientific) was used to 
transiently transfect primary mouse lung fibroblasts with microRNA mimics or 
siRNA. The cells were seeded 48 h prior to transfection into a 6-well plate until they 
reach 50% of confluency. In order to transfect the cells, the siRNA or the microRNA 
mimics were added to a solution containing 4 µl of TurboFect and 50 µl of Opti-
MEM®  serum free medium, for 20 min in RT. The solution was added to each well. 
The final concentration of microRNA mimics or control was 40 nM and the 
concentration of siRNA was 100 nM. Cells were cultured for 24 h under normal cell 
culture conditions or exposed to 5 ng/ml TGF-β1 after 24 h for additional 6- h. 
 
3.2.3 Dual luciferase reporter assay 
The dual luciferase assay, containing both the firefly luciferase and Renilla 
luciferase reporters, was used in order to assess TGF-β signaling. The NIH/3T3 cells 
were transfected with the firefly luciferase construct and with pRSL-SV40 that 
constitutively expresses Renilla luciferase, using TurboFect, followed by a 6 h 
transfection in Opti-MEM®. The cells were subsequently transfected with 40 nM of 
either control or mimic, using also TurboFect, and were incubated for 6 h in Opti-
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MEM®, after which medium was exchanged for DMEM with 10% FBS, and then 
cells were stimulated with TGF-β or vehicle. The dual luciferase ratio (DLR) was 
calculated from luminescence units generated by firefly luciferase and were 
normalized by units generated by Renilla luciferase.  
                          
3.2.4 Plasmid construction and transfection 
 The full length of Smad7 3 prime UTR containing the predicted miR-15 
family binding site was amplified by PCR from genomic mouse DNA and subcloned 
into the pmirGLO Dual luciferase microRNA target expression vector (Promega) 
between the SacI and XbaI sites. The method has been described in detail previously 
(Nicolas 2011).   The orientation and sequence of the fragment in the luciferase 
reporter were confirmed by sequencing and enzyme digestion. Transient transfections 
were performed using Turbofect, followed by a 6 h transfection in Opti-MEM®. The 
luciferase reporter construct was transfected into NIH/3T3 cells (100 nM) along with 
Renilla luciferase control reporter vector and 40 nM of either control or microRNA 
mimic. The dual luciferase ratio (DLR) was calculated from luminescence units 
generated by firefly luciferase and were normalized by units generated by Renilla 
luciferase.  
 
3.2.5 Gene expression analysis 
3.2.5.1  RNA isolation from cells and lung tissue 
Total RNA was isolated from ~ 50 mg of lung tissue using 1 ml of QIAzol®  
lysis reagent per 100 mg tissue. The lung tissue was homogenized by using Precellys® 
25 homogenizer. Subsequently, 0.3 ml of chloroform was used and the samples were 
centrifuged at 12000 g for 15 min at 4 ºC. Following centrifugation, the aqueous 
phase supernatant solution was transferred to 1.5 ml tube, and samples were mixed 
with 0.5 ml of 100% ethanol per 1 ml of QIAzol® lysis reagent, and left for 5 min at 
RT. The samples were added to an RNA column (miRNeasy kit – Qiagen) and were 
centrifuged at 10000 rpm for 2 min. The flow through was removed and the column 
was washed using buffer I and II (miRNeasy kit). 50 µl of nuclease free water were 
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added to each column, and the flow through containing the total RNA was measured 
by using NanoDrop®   ND 1000 spectrophotometer. 
Total RNA containing microRNAs from cells in culture was isolated using the 
same kit mentioned above according to the manufacturer’s instructions. The quantity 
and the quality of the RNA was measured by using NanoDrop®   ND 1000.  
 
3.2.5.2 MicroRNA microarrays 
For gene expression and microRNA expression arrays, lung homogenates 
derived from pups maintained under normoxic or hyperoxic conditions, were used for 
total RNA extraction. The microarrays comparisons were performed by IMGM 
Laboratories (Martinsfreid, Germany) using Agilent mouse microRNA microarrays 
(860K format) in combination with one-color based hybridization protocol. Signals 
on the microarrays were detected using the Agilent DNA Microarray Scanner and 
GeneSpring GX12 analysis software was used to normalize the raw data. 
 
3.2.5.3 cDNA synthesis (mRNA) 
The reverse transcription was performed on 1 µg of total RNA using MuLV 
reverse transcriptase and random hexamers (oligodeoxyribonucleotides). First, 20 µl 
of RNA was denatured at 70 ºC for 10 min, and supplemented with 20 µl of reverse 
transcription mixture. The mixture was incubated at 21 ºC for 10 min and it was 
followed by an RNA synthesis step at 43 ºC for 75 min. The final step of the reaction 
included the inactivation of the MuLV reverse transcriptase at 99 ºC. The reverse 
transcription mixture is shown below: 
 
 
Reverse transcription mixture Volume 
10× PCR buffer II 4 µl 
25 mM MgCl2 8 µl 
H2O 1 µl 
Random hexamers 2 µl 
RNase inhibitor 1 µl 
10 nM dNTP mix 2 µl 
MuLV reverse transcriptase 2 µl 
  
Total volume 20 µl 
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3.2.5.4  cDNA synthesis (microRNAs) 
The reverse transcription was performed on 1 µg of total RNA using miScript 
II (Qiagen). A reverse transcription master mix was prepared that contains all the 
components for the first-strand cDNA synthesis except template RNA. Starting with 
cDNA synthesis, the RNA was denatured for 10 min, and supplemented with the 
master mix. The solution was incubated for 60 min at 37 ºC, followed by the 
inactivation of reverse transcriptase at 95 ºC. The reverse transcription master mix is 
shown below: 
 
 
Reverse transcription mixture Volume 
5× miscript buffer 4 µl 
10× nucleic mix 2 µl 
H2O variable 
Reverse transcriptase 2 µl 
Template RNA variable 
  
Total volume 20 µl 
 
3.2.5.5  Real-time quantitative PCR (mRNA) 
The analysis of the gene expression was performed by real-time quantitative 
polymerase chain reaction (qPCR) using Platinum® SYBR® Green qPCR Supermix 
UDG kit and a StepOnePlus™ Real-Time PCR system. Primer pairs specific to the 
target mRNA were designed using Primer-BLAST software 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). The primers used are listed below: 
 
 
Gene Species Forward and reverse primer 
sequences 
 
Ctgf 
 
mouse 
 
5´- GGGCCTCTTCTGCGATTTC- 3´ 
5´- ATCCAGGCAAGTGCATTGGTA- 3´ 
 
Smad7 
 
mouse 
 
5´- GGCCGGATCTCAGGCATTC - 3´ 
5´-TTGGGTATCTGGAGTAAGGAGG -3´ 
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α-SMA 
 
mouse 
 
5´- GTCCCAGACATCAGGGAGTAA – 3´ 
5´- TCGGATACTTCAGCGTCAGGA – 3´ 
 
Hprt1 
 
mouse 
 
5´- TCAGTCAACGGGGGACATAAA – 3´ 
5´- GGGGCTGTACTGCTTAACCAG – 3´ 
 
The thermal cycling steps for the real-time PCR were as follows: 50º C for 2- 
min, 95 ºC for 5 min, 35-40 cycles of 95 ºC for 5 s, 72 ºC for 30 s. At the end of the 
program, the samples were subjected to melting curve analysis in order to exclude the 
possibility of primer/dimer formation. Hprt gene was used as a reference gene for the 
reactions. The expression of the genes was assessed with the comparative Ct method 
(ΔCt) and was calculated with the formula: ΔCt = CtReference gene – Cttarget gene  
 
3.2.6 Protein expression analysis 
 
3.2.6.1 Protein isolation 
The procedure of protein isolation was carried out carefully on ice in order to 
prevent protein degradation. The protein lysis buffer was supplemented with sodium 
orthovanadate and 1 mM Complete™ protease inhibitor mixture, right before its use. 
Next, 250 µl of protein lysis buffer was added to the NIH/3T3 or the primary 
fibroblasts seeded on 6-well plates, and cells were collected using a cell scraper into 
1.5 ml tubes and were incubated for 30/45 min on ice. The tubes were centrifuged at 
12000 rpm for 15 min at 4 ºC and the supernatant was transferred to new 1.5 ml tubes. 
In order to measure the protein concentration, samples were diluted 1:10 in nuclease 
free water and 10 µl were transferred into a 96-well plate. On the same plate, a series 
of bovine serum albumin (BSA) were also present, included as standards. On top of 
the 10 µl, 200 ml of Quick Start™ Bradford dye reagent was added to each well and 
the absorbance was measured at a 570 nm wavelength using VersaMax plate reader. 
The concentrations of the proteins were calculated for each sample using the standard 
curve.  
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Protein lysis buffer 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0.5% Igepal® CA-630 
20 M Tris-Cl, PH 7.5 
 
3.2.6.2 Protein electrophoresis and western blot 
The protein samples were mixed with 2 loading buffer and resolved by 
sodium sulfate polyacrylamide gel electrophoresis at a constant 110 mV, in running 
buffer. The proteins were blotted onto a nitrocellulose membrane at 110 mV for 1 h in 
blotting buffer. The membrane was washed with washing buffer and incubated for 45 
min in protein blocking solution at RT. The primary antibody was diluted in blocking 
buffer, and the membrane was soaked in the solution overnight at 4 ºC. The primary 
antibodies that were used in this study are listed below. The membrane was washed 
using a washing buffer, and the horseradish peroxidase-conjugated secondary 
antibody diluted in blocking solution was added. The membrane was incubated in 
solution at RT for 1 h. Thereafter, the membrane was washed and was incubated in 
SuperSignal® West Femto chemiluminescent substrate for 5 min. The protein bands 
were visualized using a LAS-4000 luminescent image analyzer. The antibodies that 
were used are listed below: 
 
 
Antibody Dilution Company Catalog number 
Anti–β-ACTIN 1:1000 Cell Signaling 
Technology, USA 
4967L 
Anti-SMAD7 1:500 Santa Cruz 
Biotechnology, 
USA 
Sc365846 
Anti-pSMAD2 1:1000 Cell Signaling 
Technology, USA 
3101 
Anti-SMAD2/3 1:1000 Cell Signaling 
Technology, USA 
3102 
Anti-α-SMA 1:1000 Abcam 5694 
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10% Resolving gel                                                                                        
10% acrylamide/bisacrylamide mixture 
375 mM Tris-Cl, pH 8.8 
0.05% SDS 
0.05% APS 
0.065% TEMED 
 
 
10 Sample buffer 
650 mM Tris-Cl, PH 6.8 
1 mM EDTA 
50% glycerol 
0.3% bromophenol blue 
9% β-mercaptoethanol 
 
 
Running buffer 
250 mM Tris-Cl, pH 8.3 
2.5 M glycine 
1% SDS
Washing buffer 
1 PBS, pH 7.2 
0.1% Tween® 20 
Stacking gel 
5% acrylamide/bisacrylamide mixture 
125 mM Tris-Cl, pH 6.8 
0.05% SDS 
0.05% APS 
0.065% TEMED 
Blocking buffer 
1 PBS, pH 7.2 
0.1% Tween® 20 
5% non-fat dry milk 
Blotting buffer 
25 mM Tris-Cl, pH 8.3 
192 mM glycine 
20% methanol 
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3.2.7  Animal experiments 
 
3.2.7.1 The mouse model of bronchopulmonary dysplasia 
All animal experiments and procedures were approved by Regierungpräsidium 
Darmstadt (approvals B2/351 and B2/1002). There was an extensive arrest of 
alveolarization in mouse pups after exposure to normobaric hyperoxia (85% O2). This 
model has been described in previous studies (Kumarasamy et al. 2009) where there 
was an extended arrest of lung development in response to hyperoxia. Both the 
normoxia (21% O2) and the hyperoxia (85% O2) groups were divided into two 
subgroups and were treated with two intraperitoneal (ip) injections of either control 
mimic (Scr) or with a mixture of miR-15b and miR-497 LNA-antagomirs at a dose of 
10 mg/kg dissolved in water, on day 1 and 3; Nursing dams were exchanged every 24 
h between normoxia and hyperoxia in order to minimize oxygen toxicity. Dams and 
pups received food ad libitum and were maintained on 12 h light dark cycle. Pups 
were sacrificed on the fourteenth day after birth (P14) by the use of isofluorane 
followed by lung extraction.   
 
3.2.7.2 Lung stereology 
The American Thoracic Society/European Respiratory has recently published 
specific recommendations for the assessment of lung structure (Hsia et al. 2010). The 
mouse lungs were fixed via a tracheal cannula at a stable hydrostatic pressure of 20 
cmH2O, using a solution containing 1.5% (wt/vol) paraformaldehyde, 1.5 % (wt/vol) 
glutaraldehyde in 150 mM HEPES, for 24 h at 4 C. The lung volume was measured 
by water displacement and the results were confirmed by applying Cavalieri’s 
principle (Tschanz et al. 2011). Following a systematic uniform randomization (SUR) 
rule, the tissue blocks were embedded in glycol methacrylate (Technovit 7100) in 
order to eliminate the standard error derived from tissue shrinkage. Slices were cut 
from each block (thickness of 2 m), mounted on slides and were stained using 
Richardson’s stain; every first and third section were chosen for analysis and were 
digitally scanned using the NanoZoomerXR digital slide scanner. The lung structure 
analysis was carried out using the most updated version of Visiopharm NewCast 
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stereology software (VIS 4.5.3). The stereological assessment of surface density, 
mean linear intercept and septal thickness was carried out with a magnification of 
20; initially a test grid with counting points (crosses) was used to count on 
microscopic digital images generated by SUR. As depicted in Figure 3-1 A, the test 
points fall either on airspaces P(A) or on septal tissue P(sep). This allows an estimation 
of the volume fraction of airspaces Vv(air,par) and septal tissue Vv(sep,par) within 
parenchyma. In the next step, linear intercepts were measured on the same digital 
images by using a line segment of approximately 70 m that was projected on the 
image with a random orientation (Fig 3-1 B). A measurement was performed each 
time the line intersected an alveolar surface (marked as I) and also when the two 
endpoints of the line were within the parenchyma, taken as points (marked as P). 
After counting 60 to 100 fields and obtaining around 150 count points and 
intersections, the mean linear intercept (MLI) was obtained; this is the mean free 
distance in the airspaces in the lung (Knudsen et al. 2010). The second important 
parameter that can be calculated by using the above parameters is septal thickness 
(St).  
In order to define the total alveoli number in the mouse lungs, the physical dissector 
methodology was used. As depicted in Figure 3-1 C and D, a counting frame is 
projected on the digital images, taken from the first and the third sections in a 
consecutive series of serial sections, each of 2 m thickness. When there is an 
alveolar opening open in one section and closed in the other section or vice versa, this 
is counted as a bridge (marked as B). After counting 60 to 100 fields (marked as M), 
the number of bridges is used in a formula to obtain the total number of alveoli.  
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Figure 3-1 Stereological analysis of neonatal mouse lungs.  
A: An example of a point grid projected on the digital image from a mouse lung  at P14, 
that was exposed to hyperoxia . When the crosses fall on airspaces, are counted as P( A) 
or when crosses fall on septa are counted as P( sep). These counts give the first 
estimation of volume fractions within parenchyma.  B: a system consisting of a line 
segment with a length of 72.49 µm. When the endpoints of the line  fall  within the 
parenchyma are counted (P) and also the number of intersections of the line with the 
alveolar surface (I). C and D: A counting frame is projected over the image in both 
fields of view. Alveolar bridges (B) are counted in every field  (M).  
 
 
 
 
 
 
  
A B 
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3.3 Statistical analyses 
Values are presented as mean  SEM. Statistical comparisons between means 
of two groups were performed using unpaired Student’s t-tests. For multiple 
comparisons, statistical analysis was performed using 1-way ANOVA followed by 
Bonferroni post hoc test. P values are considered significant below 0.05. The software 
used for the statistical calculations are GraphPad/Prism (GraphPad Prism version 6.00 
for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com) and 
R(http://cran.r-project.org/).
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4 Results  
4.1    Secondary septation peaks at P5.5 in mice  
In order to investigate the post-natal (P) time point that secondary septation 
peaks, mouse lungs were extracted in different time points and were stained, as 
depicted in Figure 4-1. Postnatal 2.5 and P3.5 represent stages before the peak of 
secondary septation, P5.5 represents the peak of secondary septation and P14.5 
represents the stage in which the alveolarization is almost complete. The lung 
structure looks more complicated with definitive alveoli already being formed. 
 
 
Figure 4-1 H&E sections representing the stages before, during and after 
secondary septation. The red arrows in P5.5  point on the newly-formed secondary 
septa.  
 
The above finding indicates the most important time points where the study can focus 
on. The peak of septation takes place within six days after birth and is almost 
complete on P14.5. Studies have reported that alveolarization can continue until 
adulthood (Mund et al. 2008).  
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4.2 Expression analysis of microRNAs under normoxic 
conditions 
As an initial screening, an unbiased screen by microarray of microRNA 
expression was performed on lung tissue from pups under normoxic conditions. The 
time points that were chosen for the screening were indicated above (P2.5, P3.5, P5.5, 
P14.5). The microRNAs that were distinguished by a high level of expression in all 
four time points were miR-15b, miR-5097, miR-136, miR-541, miR-18a, miR-210 
and miR-154. MiR-127 was the microRNA with the most dramatic changes between 
different time points. Baskaran et al. has reported that miR-127 showed the highest 
expression just before and after birth in the lungs extracted from rats (Bhaskaran et al. 
2009). The total number of microRNAs that had at least one significant change in the 
expression level between the four time points was 67; the microRNAs are presented 
in Figure 4-2. 
 
 
 
 
Figure 4-2 Expression patterns of microRNAs during late lung development using 
a color heat map.  
Data were subjected to significant analysis of microarrays (SAM). Every row 
represents a time point and every column a microRNA. Each value of expression is the 
average of 4 samples and  is log2 transformed. The red represents high intensity values, 
the blue low intensity values.   
Most regulated microRNAs 
  
43 
 
4.3 Expression analysis of microRNAs after exposure to 
hyperoxia 
Later on, an unbiased screen by microarray of microRNA expression was 
performed on lung tissue from pups exposed to 21% O2 and 85% O2 during the four 
time points. The data clearly demonstrate that hyperoxia, as employed in the BPD 
model, has a dramatic and rapid impact on microRNA expression, with possible 
consequences for the development of the lung. In this study, a total number of 55 
microRNAs showed a significant deregulation indicating a possible role in a 
pathological condition such as BPD (Fig 4-3).    
 
 
Figure 4-3 Whole lung homogenates were screened for changes in microRNA 
expression after exposing mouse pups to hyperoxia .  A total number of 55 
microRNAs showed significant de -regulation in all four timepoints.  
 
The microRNAs with an increased expression, compared to normoxia, are 
shown in Table 4-1. The up-regulated microRNAs were interesting candidates for 
further investigation; the reason is that antisense oligonucleotides are easy to be 
constructed and can be used to inhibit microRNA expression in vivo.  
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Table 4-1  MicroRNAs with increased expression after exposure to hyperoxia .   
The values underneath the  systematic name represent the P  value after performing an 
unpaired Student’s  t-test between normoxia and hyperoxia groups  (n=4).  
 
P 2.5 P 3.5    P 5.5 
miR-15b  
(0.02)   
miR-15b       
(0.04) 
  miR-34a 
  (0.0003) 
miR-363  
(0.02) 
miR-497 
(0.001) 
  miR-135b 
  (<0.0001) 
miR-200a*   
(0.02) 
miR-200a* 
(0.003) 
  miR-34b-3p 
  (0.00027) 
 miR-33 
(0.001) 
    miR-29c 
  (<0.0001) 
 
 
 
4.4 The microRNA-15 family expression is deregulated after 
exposure to hyperoxia                   
In microarrays,  miR-15b appeared in two time points;  miR-497 appeared 
only once, but both molecules belong to the same microRNA family (Yue and Tigyi 
2010) and for that reason were chosen as candidates for further investigation. The 
relationship between the expression levels of both microRNAs during hyperoxia was 
positive and strong, revealing a possible common pattern of transcription. Both 
microRNAs are transcribed from different chromosomes but the expression is highly 
correlated as depicted in Figure 4-4. This is an important finding indicating similar 
transcription patterns of molecules that belong to the same family.   
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Figure 4-4 Analysis of the relationship between miR-15b and miR-497 expression 
after exposure to hyperoxia.  
Correlation of expression fold changes of miR-15b and miR-497, under hyperoxic 
conditions, was assessed  (n=4, per group). Proportion of variability was determined by 
calculating the Pearson coefficient of determination (R 2).  
 
Mir-15 family expression, under normoxic and hyperoxic conditions, was 
validated by real time RT-PCR. The expression analysis included all six members of 
the miR-15 family; all members were initially up-regulated after exposure to 
hyperoxia with miR-15b and miR-497 being the most up-regulated (Fig 4-5, B and 
C). During the peak of secondary septation, the expression levels of most of the 
members were normalized to levels observed under normoxic conditions, and then 
were elevated again in P14.5, as depicted in Figure 4-5. 
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Figure 4-5 Differential expression of the microRNA-15 members under normoxia 
versus hyperoxia .   
Expression levels of miR-15 family members  were assessed by real time RT-PCR in 
the mouse lungs (n=6, per group)  in normoxia versus hyperoxia. The five members 
share the same ‘seed’ sequence although are transcribed from different  gene clusters. 
Data are expressed as mean ± SEM.  Nox, normoxia; Hyx, hyperoxia.  P values were 
determined by 1-way ANOVA with a Bonferroni post hoc test .  
 
In P2.5, miR-15b and miR-497 had a significant difference in expression 
levels between normoxia and hyperoxia and were interesting candidates for further 
investigation.  
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4.5 The microRNA-15 family expression in primary lung cells 
The next step was to identify in which cell-type miR-15b and miR-497 were 
mostly expressed. For that reason five major cell-types in the lung (Crapo et al. 1982) 
were used for the microRNA screening. As depicted in Figure 4-6, both miR-15b and 
miR-497 were expressed in a similar pattern in all cell-types derived from murine 
lungs, with no significant differences. 
 
 
   A                                                                B 
Figure 4-6  Expression of miR-15b and miR-497 in five primary lung cell types . 
Assessment of expression of miR-15 (A) and miR-497 (B) by real time RT-PCR (n=3, per cell-type). 
Data are expressed as mean ± SEM. snRNA, small nuclear RNA; AEC II, alveolar epithelial cells; 
SMC, smooth muscle cells. 1 – way ANOVA was used as a statistical comparison method. 
The expression analysis suggests equal expression levels in every cell-type, however 
both miR-15b and miR-497 are transcribed from different chromosomes (Chamorro-
Jorganes et al. 2011). It has been reported that the expression level of microRNAs 
depends on the expression of target mRNAs and can be tissue specific (Sood et al. 
2006). 
 
4.6 Target identification using computational methods 
The functions of microRNAs are mediated by the ability to inhibit the 
expression of target mRNAs (Valencia-Sanchez et al. 2006). Identification of gene 
targets is a very important step in order to understand the role of microRNAs in gene 
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regulatory networks. One of the most common screening approaches for microRNA 
targets is in silico, based on computational algorithms comparing ‘seed’ sequences 
with conservational sites on the 3 prime untranslated regions (UTR) of genes 
(Friedman et al. 2009). Base pairing between microRNAs and  targets, is analyzed 
and is based on many factors such as stable binding of 5 prime end of the microRNA, 
the thermodynamic binding of the two molecules through calculation of free energy 
(Watanabe et al. 2007).  
In this study, for the identification of gene targets, the miRWalk algorithm 
(https://www.umm.uni-heidelberg.de) was used; this is a publicly available library of 
predicted and validated microRNA targets. The miRWalk algorithm lists all the 
possible targets obtained by using four major established algorithms such as 
Targetscan, miRanda, RNA22, miRDB. The illustration in Figure 4-7 represents the 
strategy designed to identify possible mRNA targets. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 Illustration of the strategy being employed in order to identify 
microRNA targets.  
 MicroRNAs are checked by the ‘seed’ sequence, using the miRWalk algorithm. Some of the predicted 
targets of both microRNAs overlap which shows clearly that both miR-15b and miR-497 belong to the 
same family and share the same ‘seed’ sequence.  
         miRWalk 
                         
15b  497 
  
Gene enrichmentG 
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Computational prediction of microRNA targets usually returns many results. 
For this reason, all the predicted targets that resulted by using the four algorithms 
mentioned above, were enriched in order to eliminate inaccurate results. After 
enrichment using R software, 63 target genes overlapped from all four computational 
algorithms as shown in Figure 4-8. 
 
 
Figure 4-8 Gene target enrichment for the microRNA-15 family .  
The target prediction algorithms that were employed returned  hundreds of target 
candidates. In total 63 genes were common in all  four algorithms.  
 
  MiRWalk microRNA prediction targets are depicted in Table 4-2 and are 
based on the probability of the microRNA-mRNA interaction. The table represents 
the gene target identification, the number of mRNA nucleotides that the microRNA 
binds, the miR ‘seed’ nucleotide sequence, the 3 prime UTR position and the P value 
showing the probability of this interaction. Smad7, a gene implicated in TGF-β 
signaling, is highlighted in the table as a target candidate.  
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Table 4-2 In silico analysis reveals miR-15 family target genes . 
This is only a sample of candidate genes introduced as targets of miR-15 family. 
Smad7  is highlighted as a candidate for the study. The table contains the  miR, target 
gene, accession gene number , ‘seed’ sequence length, position, the region and the 
statist ical P value.  
 
 
 
 
 The Smad7 gene plays an important role in TGF-β signaling and has a 
significant impact on organogenesis, cell cycle and development (Briones-Orta et al. 
2011). As TGF-β has such an impact on late lung development and alveolarization 
(Alejandre-Alcazar et al. 2007), the relationship between miR-15 family and Smad7 
was further explored.   
 
4.7 Smad7 is a direct target of miR-15b  
The validation of the computational prediction is important for understanding 
the biological significance of the microRNAs. In order to validate the hypothesis that 
Smad7 is an actual target of miR-15 family, a luciferase reporter vector containing 
Smad7 3 prime UTR was used. Since fibroblasts are highly responsive to TGF-β, an 
experiment was performed using fibroblast NIH/3T3 cell lines. The NIH/3T3 cells 
were transfected using a miR-15b mimic, and a down-regulation of luciferase activity 
was observed, indicating that Smad7 is a direct target of miR-15b (Fig 4-9).    
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Figure 4-9 Smad7  is a direct target of miR-15b.  
NIH/3T3 cells were co-transfected with the 3 prime UTR Smad7  vector or an empty 
vector (not containing a 3 prime UTR) and 40nM of miR-15b, or control mimic (Scr).  
The luciferase ratio was calculated from luminescence units g enerated by firefly and 
were normalized by units generated by Renilla  luciferase. EV, empty vector; UTR, 
untraslated region.  P values were determined by 1-way ANOVA with a Bonferroni post 
hoc test.   
 
 
4.8 MiR-15b regulates TGF-β signaling through Smad7 
After validating the direct binding of miR-15b to the Smad7 3 prime UTR, it 
was hypothesized that miR-15b has an impact on TGF-β signaling. To explore 
whether the miR-15b regulates the canonical TGF-β pathway, a CAGA luciferase 
reporter was used, with a Smad3-responsive element cloned into the pGL3-Basic 
vector, upstream of the luciferase gene. Overexpression of miR-15b, or transfection of 
Smad7 siRNA, after TGF-β stimulation, led to an increase in luciferase activity in 
NIH/3T3 cells (Fig 4-10). These data support the fact that miR-15b has a similar 
effect as Smad7 siRNA and leads to phosphorylation of SMAD2 and SMAD3 with a 
consequent increase of TGF-β signaling. This is the first in vitro evidence that the 
miR-15b induces the canonical TGF-β pathway. MiR-497 has an identical ‘seed’ 
52 
sequence as miR-15b, so it was hypothesized that the impact on TGF-β signaling is 
similar. 
Figure 4-10 miR-15b overexpression modulates TGF-β signaling in NIH/3T3 cells .   
NIH/3T3 cells were transfected either with 40 nM control or miR-15b mimic or 100 nM 
Smad7 siRNA, and the effects on TGF-β signaling were assessed by using a Dual 
luciferase assay employing p(CAGA) 9 -luc and pRL-SV40. The cells were stimulated 
either with vehicle or with 5 ng/ml of TGF -β for 24h.  The data represent means ± 
SEM (n=6).  P values were determined by 1 -way ANOVA with a Bonferroni post hoc 
test. 
Following the experimental validation that miR-15b modulates TGF-β 
signaling, the next step was to evaluate whether miR-15b and miR-497 
overexpression has an impact on Smad7 expression. For this reason, primary mouse 
lung fibroblasts were isolated and were transfected with microRNA mimics or control 
mimics. As depicted in Figure 4-11, overexpression of both miR-15b and miR-497 
resulted in decreased Smad7 mRNA (Fig 4-11 A) and protein levels (Fig 4-11 B). 
This finding also represents the identical functionality of both microRNAs.  
  
53 
 
 
        A                                                                 B 
S
m
a
d
7
 e
x
p
re
s
s
io
n
 (

C
t)
S
c r
m
iR
-1
5
b
m
iR
-4
9
7
-4
-3
-2
-1
0
P  =  0 .0 5 1
P  =  0 .0 3 9 1
 
 
Figure 4-11 Impact of miR-15b and miR-497 overexpression on Smad7  expression 
in primary lung fibroblasts.   
Cells were transfected with  40  nM of control mimic (Scr), or miR-15b or miR-497 
mimic for 24 h. (A) Expression analysis of the Smad7  gene was assessed in primary 
fibroblasts after transfection, by real -time RT-PCR (n = 6, per group). (B) Total 
cellular protein was isolated, subjected to immunoblot  with antibodies against SMAD7 
and β-ACTIN. Data are expressed as mean ± SEM .   P values were determined by using 
1-way ANOVA with a Bonferroni post hoc test .       
 
4.9 MiR-15b and miR-497 overexpression increases the 
differentiation of fibroblasts to myofibroblasts 
Differentiation and plasticity in various cells is dependent on the 
microenvironment. Fibroblasts are important participants in processes such as injury, 
inflammation and remodeling (Fallowfield 2011). Fibroblasts are characterized by a 
unique ability to transdifferentiate between different types with various functionalities 
(Sappino et al. 1990). It has been reported previously that administration of TGF-β in 
rats resulted in the formation of a granulation tissue, in which, α-SMA expressing 
myofibroblasts were abundant (Desmouliere et al. 1993).  
Provided that miR-15b and miR-497 have an impact on Smad7 expression, it 
was hypothesized that both molecules have an impact on fibroblast differentiation. 
Primary lung fibroblasts were transfected with microRNA mimics or control mimics. 
The cells were transfected for 24 h and the expression levels of α-SMA was evaluated 
Scr miR-15b 
Smad7 46 kDa 
42 kDa  - actin 
46 kDa Smad7 
Scr miR-497 
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(Fig 4-12). Transfection with miR-15b and miR-497 using normal media increased α-
SMA expression (Fig 4-12 A). When cells were stimulated with TGF-β for 12 h, the 
change in expression levels of α-SMA between groups remained the same but the 
expression baseline was elevated (Fig 4-12 B). In order to evaluate whether α-SMA 
up-regulation is TGF-β dependent, prior to the application of mimic, the inhibitor 
SB431542 was used. This is a selective inhibitor of the TGFBRI, ALK4, ALK5 and 
ALK7. There was no change in α-SMA levels, an indication that both microRNAs act 
through the canonical TGF-β pathway (Fig 4-12 C).  
 
 
Figure 4-12 Impact of miR-15b and miR-497 on α-SMA  in primary lung fibroblasts 
is TGF-β  dependent .   
Fibroblasts were transfected with 40 nM of control mimic (Scr), or miR -15b or miR-
497 mimic for 24 h. Expression analysis of α-SMA gene was assessed, by real -time RT-
PCR (n =4, per group). The cells were stimulated  either with vehicle (A) or 5 ng/ml of 
TGF-β for 12 h (B), or  treated with 10 nM SB431542 before transfection  (C). Data are 
expressed as mean ±  SEM. P values were determined by using 1 -way ANOVA with a 
Bonferroni post hoc test.  
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In order to evaluate the impact of both microRNAs on the α-SMA protein 
level, primary lung fibroblasts were transfected with microRNAs and were stimulated 
with TGF-β. The cells were subjected to immunofluorescence analysis of α-SMA; 
both microRNAs caused an increased fluorescence intensity of a-SMA (Fig 4-13). 
  
 
 
 
Figure 4-13 Impact of miR-15b and miR-497 on α-SMA protein levels in primary lung 
fibroblasts. 
Fibroblasts were transfected with 40 nM control mimic (Scr) (A), or with miR-15b (B) or with miR-
497 (C) for 24 h. Following transfection, 5 ng/ml of TGF-β was added to the transfection medium for 
additional 6 h. Immunolocalization of α-SMA (green); nuclei were stained using DAPI (blue). Images 
are at 10  magnification.   
 
 
 
A 
A 
A 
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4.10 In vivo inhibition of miR-15b and miR-497 after exposure 
to hyperoxia is associated with an improved lung 
morphology  
 To investigate whether modulation of microRNA expression in vivo has an 
effect on lung structure, LNA-antagomirs against miR-15b and miR-497 were 
administered to mouse pups after birth.  
The setup of the in vivo experiment was as follow: Mouse pups were divided and 
randomized into four different groups. Two groups were exposed to hyperoxia (85% 
O2) and the other two to normoxia (21% O2).  One group under normoxic and one 
under hyperoxic conditions were injected intraperitoneal with a control mimic 
microRNA (Scr) and the other two groups were injected with a mixture containing 
LNA-antagomir-15b and LNA-antagomir-497. The mouse pups were injected on P1 
and on P3. Figure 4-14 A depicts the experimental set up. There are several studies 
that have reported efficient and long-lasting silencing of microRNAs using LNA-
antagomirs (Stenvang et al. 2012). In the current study, two ip injections were given 
in two different dosages, 10 mg/kg and 20 mg/kg. The antagomirs reached the lung by 
P3 and efficiently down-regulated the target microRNA. As the purpose of this study 
was to lower slightly the expression (normalizing the increase in the expression 
observed after exposure to hyperoxia), the 10 mg/kg dosage was applied. The 
microRNA expression remained at a lower level until P14, proving the fact that 
antagomirs have a long lasting effect (Fig 4-14 B and C). 
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     A 
  B   C 
Figure 4-14  Experimental set up and an LNA-antagomir dosage response . 
Pups were born and were injected intraperitoneal ly with 10 mg/kg on P1 and P3. Two 
dosages were used (10 and 20 mg/kg respecti vely) in order to determine the 
concentration for the purpose of the study. The expres sion level of miR-15b was 
analysed 48 h after the first injection (B) and on day P14 (C), prior to the extraction of 
the lungs . LNA, locked nucleic acid; Data are expressed as mean ±  SEM. P values 
were determined by using 1-way ANOVA with a Bonferroni post hoc test. 
The lungs were extracted on P14 and were analyzed stereologicaly using the 
Visiopharm software (VIS 4.5.3). Figure 4-15 depicts the lung tissue sections from 
mouse pups exposed to either normoxia or hyperoxia for 14 days, treated with 
controls or LNA-antagomirs. The lung structure was evaluated by various lung 
morphological parameters; there was a significant decrease in mean linear intercept 
(Fig 4-15 E) and a profound increase in alveoli number (Fig 4-15 F). 
Birth LNA-antagomirs 
miR knockdown/ 
target regulation 
Day  1  3  14 
10 mg/kg 
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Figure 4-15 LNA-antagomir administration improved perturbed alveolar 
development after exposure to hyperoxia .  
 Mice were exposed to 21% O 2  or 85% O2  for 14 days after birth, and received either 
control mimic or LNA-antagomirs mixed solution. Representative lung sections from 
mice at day P14, that were exposed to 21% O 2 (A and B) or  85% O2   (C and D), with 
an administration of either a control  mimic (A and C) or an LNA-antagomir mix (B and 
D). Lungs from all 4 groups were assessed for different lung structural parameters,  
including mean linear intercept (E), alveoli number (F) and septal wall thickness (G). 
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Data are presented as mean ± SEM (n=6, per group). P values were determined by 
using 1-way ANOVA with a Bonferonni post hoc test.  
 
The septal thickness had no significant change but it expressed a tendency towards 
thickening of the septa. That possibly correlates with the fact that a down-regulation 
of miR-15b and miR-497 leads to an overexpression of proliferating genes as has 
been reported previously (Porrello et al. 2011).  
 
 
4.11 In vivo inhibition of miR-15b and miR-497 decreases TGF-
β signaling 
To study the effect of the LNA-antagomirs on TGF-β signaling, groups 
exposed to normoxia or hyperoxia and treated either with controls or LNA-
antagomirs, were investigated for the activation of TGF-β signaling pathway. The 
TGF-β signaling was elevated in the hyperoxia group compared to normoxia and it 
was decreased in the hyperoxia group treated with LNA-antagomirs (Fig 4-16).  
 
 
 
 
Figure 4-16 Administration of LNA-antagomirs modulates TGF-β  signaling in 
mouse lungs.  
Total cellular proteins were isolated from lungs derived from mouse pups exposed to 
normoxia or hyperoxia and treated either with controls or LNA -antagomirs for the first 
14 days of life, subjected to immunoblot  with antibodies against pSMAD2 relative to 
SMAD2/3 and β-ACTIN .  pSmad2, phosphorylated Smad2;       
To confirm that TGF-β signaling decreased after administration of the LNA-
antagomirs, the expression level of a downstream ECM–related target gene of TGF-β 
signaling was evaluated, by real-time RT-PCR. The connective tissue growth factor 
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(CTGF) is a downstream gene of TGF-β signaling highly expressed in fibroblasts. 
Ctgf has been associated with TGF-β and exacerbated ECM production in conditions 
such as fibrosis (Brigstock 2010). Ctgf expression was up-regulated after exposure to 
hyperoxia and was normalized after administration of the LNA-antagomirs (Fig 4-17) 
and the finding is correlated with the data presented previously.  
 
 
Figure 4-17 Inhibition of miR-15b and miR-497 modulates the expression of TGF-β ECM 
target gene.  
To assess whether the LNA-antagomir administration has an effect on downstream TGF-β 
targets, mouse tissues were harvested for analysis on P14. The ctgf expression was assessed by 
real-time RT-PCR in the lungs of LNA-antagomir treated and control treated mice. Data are 
expressed as mean ± SEM. P values were determined by using 1-way ANOVA with a Bonferonni 
post hoc test 
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5 Discussion 
It has been nearly 40 years since the first clinical description of BPD, but still remains 
one of the major complications of premature birth, bearing high costs (Short et al. 2003). 
Within the last decade, progress has been made but the main clinical implications persist and 
additional research is required to improve the outcomes of a treatment. Few of the promising 
scientific fields focus on stem cells and on various molecular mechanisms including 
epigenetic regulation. MicroRNAs are known as strong epigenetic modulators and since their 
discovery, research has reported that hundreds of microRNAs are implicated in various 
physiological processes in the body including the lung. The knowledge of microRNA 
involvement in the development of the lung is limited; most studies concerning the 
development of the lung are limited to expression level screening profiles at various stages of 
embryonic and late lung development (Dong et al. 2012, Lu J. et al. 2005, Williams et al. 
2007). MicroRNAs such as miR-17-92 cluster (Carraro et al. 2009) can regulate gene 
expression responsible for epithelial differentiation and acts on branching morphogenesis 
during early lung development. In the current study, the dynamics and the possible roles of 
microRNAs during late lung development were explored. One microRNA can regulate the 
translation of hundreds of genes (Winter et al. 2009); however one microRNA may not be 
sufficient to inhibit translation, and several other microRNA species are required to bind to 
the mRNA repressing the expression. In the beginning of the microRNA exploration, it was 
thought that microRNAs bound to the RISC were able to inhibit protein synthesis by 
blocking protein elongation (Olsen and Ambros 1999). Most recent evidence suggested that 
microRNAs induce target instability. The microRNA-RISC complex initiates the degradation 
of mRNA by transferring it from cytosol to “P-bodies”, sites of RNA degradation (Liu J. et 
al. 2005). Thus, microRNAs inhibit the initiation of mRNA translation into protein.  
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5.1 MicroRNA-15 family expression is regulated after exposure to 
hyperoxia 
MicroRNAs are involved in numerous biological processes but the knowledge of 
microRNA involvement in lung development is limited. Mice and rats with targeted de-
regulation of microRNA processing develop severe developmental anomalies but the 
mechanisms of action in these processes are not well established (Mattes et al. 2008). The 
generation of transgenic animals is very promising regarding the expansion of knowledge on 
these mechanisms. For example the importance of miR-17-92 cluster was described in 
various transgenic mouse models with the knock-out resulting in postnatal lethality (Ventura 
et al. 2008).    
In the current study, expression profiling of microRNAs during normal lung 
development and in lungs exposed to hyperoxia, revealed a significant number of de-
regulated microRNA molecules that might play a role in modulating processes during the 
alveolar phase. MicroRNA-15 family expression was stably elevated during development 
under normoxic conditions and was highly up-regulated before the peak of secondary 
septation in mice. This elevated expression of microRNA-15 family may be functionally 
important in regulating homeostasis and various processes within the lung. In total, 67 
microRNAs were deregulated during normal lung development and 55 microRNAs were 
deregulated after exposure to 85% O2 for 14 days after birth. In silico target prediction 
analysis of miR-15b and miR-497 revealed 63 common gene targets with Smad7 being one of 
the top candidates.   
 
5.2 MicroRNA-15 family down-regulates Smad7 expression and 
enhances TGF-β canonical signaling in vitro 
MiR-15b and miR-497, two of the most up-regulated microRNAs after exposure to 
hyperoxia, were chosen for this study with the hypothesis that modulate TGF-β signaling, a 
critical signaling network in various processes such as proliferation, apoptosis, cell cycle and 
overall development (Massague 2012). Several studies have reported that alterations in 
Smad7 expression have been implicated in various human diseases and a potential therapeutic 
treatment could focus on controlling gene activity and stability (Gronroos et al. 2002, 
Simonsson et al. 2005). One of these studies focused on the development of antisense 
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inhibitors for the prevention and treatment of central nervous system such as sclerosis or 
immune encephalomyelitis  (Kleiter et al. 2007).  
Concerning fibrosis, there were two drugs that are able to restore normal levels of Smad7 and 
have been proposed as therapeutic agents against interstitial fibrosis (Lu M. et al. 2009, Ning 
et al. 2009). One is enalapril and is an angiotensin converting enzyme and it is used in the 
treatment of hypertension; the second is tetramethylpyrazine and it is derived from a Chinese 
herb used in preventing ischemia. Both drugs were able to decrease the accumulation of 
lesions in the kidney through an up-regulation of Smad7 protein expression (Lu M. et al. 
2009).    
The conclusion of these studies supports the fact that a tuned balance between TGF-β 
and Smad7 is important in maintaining homeostasis. Thus, any alteration of this balance can 
lead to the development of human diseases.      
In the current study, in vitro experiments including a luciferase assay revealed the 
direct association of miR-15b and Smad7 and the impact on TGF-β signaling. 
Overexpression of miR-15b and miR-497 in primary fibroblasts led to a decrease of Smad7 
mRNA and protein level and to an increase of TGF-β signaling. Hibio et al. have previously 
suggested that microRNAs with the same ‘seed’ sequence but different duplex structure have 
different efficacies and that depends on the melting temperature value of the microRNA 
sequence (Hibio et al. 2012). More specifically Hibio et al. have reported that the silencing 
efficacy of the microRNA is correlated to the melting temperature; the higher the 
temperature, the higher the efficacy. In the current study miR-15b and miR-497 share the 
same ‘seed’ sequence and target identical genes. However both microRNAs differ in the total 
sequence structure so it is assumed that the impact on genes differs. In that context, miR-497 
possesses a higher melting temperature value.   
 Fibroblast to myofibroblast differentiation is known to be regulated by TGF-β and it is a 
critical procedure, dependent on the nature of cellular microenvironment, and is strongly 
associated with the secondary septation and the formation of definitive alveoli (Choi 2010). 
Alterations in the microenvironment occur during lung injury, inflammation and repair 
(Thannickal et al. 2003). Fibroblasts play an important role in such changes and can undergo 
between different cell types such as lipofibroblasts and myofibroblasts. Lipofibroblasts 
contain triglycerides, cholesterol esters and retinyl esters, and are localized at the base of 
elongating septa during alveolarization (Torday et al. 1995, Vaccaro and Brody 1978). 
Myofibroblasts are the source of septal elastin, are characterized by expressing markers 
between fibroblasts and smooth muscle cells and they possess an ability of expressing 
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contractile proteins such as α-SMA (Powell 2000). Persistent proliferation of myofibroblasts 
can lead to fibrotic diseases (Hardie et al. 2009) but also the lack of myofibroblasts lead to 
decreased alveolarization (Bostrom et al. 1996). Myofibroblasts are located in the developing 
secondary septa and the septal tips during the alveolar phase and for that reason are 
characterized as alveolar myofibroblasts (Dickie et al. 2008). In this study, overexpression of 
miR-15b and miR-497 in primary lung fibroblasts led to increased TGF-β signaling and an 
increase in α-SMA expression. The increase of microRNA-15 family members during 
hyperoxia, suggests that it is a part of a regulatory mechanism to increase TGF-β activity.   
   
     
5.3 In vivo inhibition of miR15b and miR-497 improves lung 
structure and increases alveolarization    
The use of antisense oligonucleotides is a promising approach that belongs to antisense 
therapy and there are two antisense oligonucleotides that have approved by the FDA (Perry 
and Balfour 1999, Santos et al. 2015). Antisense therapy can be used against various genetic 
diseases and it is a technique similar to RNA interference (RNAi), although the main 
mechanism differs. The development of antisense oligonucleotides can also be against 
microRNAs, with the form of locked nucleic acids (LNA), which allowed the researchers to 
modulate the expression of microRNAs. This interference was an indirect way to act 
simultaneously on the expression of hundreds of genes, suggesting greater responses in 
various diseases. Inhibition of microRNAs in vivo was first described by Hutvagner et al. 
(Hutvagner et al. 2004); in this study, antisense oligonucleotides complementary to let-7, 
were injected to C. elegans leading to a loss of function. The use of 3’ cholesterol-
conjugated, 2’-O-Me oligonucleotides called antagomirs was described in 2005 by Krutzfeldt 
et al. The administration of three tail vein injections of antagomir-16 resulted in inhibition of 
miR-16 in the kidney, liver, lung, heart, skeletal muscle, skin, fat, bone marrow and adrenal 
glands but not in the brain (Krutzfeldt et al. 2005). Furthermore, inhibition of miR-16 in the 
brain was accomplished by delivery of antagomir-16 in the mouse cortex. The recent 
development of LNAs was a result of multiple chemical modifications, improving nuclease 
resistance of the oligonucleotides and increasing the binding affinity to target microRNAs. In 
a study by Porello et al., microRNA-15 family was reported to regulate the expression of a 
number of cell cycle genes; this association suggested that inhibition of the microRNA-15 
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family with the use of LNA-antagomirs might increase proliferation of cardiomyocytes and 
decrease infarct sizes. Indeed, the LNA-antagomirs increased regeneration of the infarcted 
myocardium due to the proliferation of cardiomyocytes (Porrello et al. 2011).  
In the current study, in vivo inhibition of two members of the microRNA-15 family 
led to three important findings. First, miR-15b and miR-497 expression was efficiently 
normalized during hyperoxia, by injecting 15-mer LNAs intraperitoneal in mouse pups. 
Second, inhibition of both microRNAs improved lung morphology by reducing mean linear 
intercept, increasing alveoli number by almost 50%, but had no impact on septal thickness. 
One major characteristic of BPD is the thickening of the septa (Bourbon et al. 2005), a 
characteristic that was not improved after treatment in hyperoxia group. Third, inhibition of 
both molecules, following LNA administration, decreased TGF-β signaling and the 
expression of Ctgf, a downstream ECM-related gene. The present study is unique in 
administering LNAs in a mouse model exposed to hyperoxia with an extensive lung injury 
and the proposed scheme is depicted in Figure 5-1. It should be noted that microRNAs have 
many targets and the present study does not indicate the unique contribution of Smad7 in 
LNA-antagomir treated mice, resulting in the overall improvement of the lung structure. 
Further in vivo studies including knock out models of the specific microRNA species, the use 
of LNA based target site blockers are necessary to support this evidence. However, the up-
regulation in the expression of microRNA-15 family target genes after antagomir 
administration, is correlated to proliferation, cell cycle, apoptosis and differentiation (Porrello 
et al. 2011) and it is likely to contribute to the lung improvement being observed.  
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Figure 5-1 Model of TGF-β signaling  regulation by using LNA-antagomirs after exposure 
to hyperoxia.   
The antagomirs against miR-15b and miR-497 increase the expression of Smad7 and inhibit  
the phosphorylation of Smad2/3/4 complex. The microRNA inhibition has an impact on 
fibroblast differentiation and lung structure.  TGF-βR, Transforming growth factor beta 
receptor; P, phosphorylation;   
 
In summary, this study is the first evidence of the functionality of microRNAs in late 
lung development and that inhibition can improve lung morphology in mice exposed to 
hyperoxia from P1 to P14. Given the fact that antisense oligonucleotides entered the clinical 
trials, this methodology has a potential for translation (Sharma et al. 2014).    
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6 Summary 
MicroRNAs are key regulators of organogenesis and during the last years many 
studies focused on microRNA expression during embryonic development. To date, there is 
no study to report possible roles of microRNAs in late lung development and especially 
during the alveolarization process.  
The objective of this study was to identify microRNAs that are deregulated under 
hyperoxic conditions and to assess whether microRNA expression can be modulated in vivo. 
Lung microRNA expression screening was assessed at four time points under normoxic 
conditions by microRNA microarray; the time points were P2.5 and P3.5 (pre-septation), 
P5.5 (peak septation) and P14.5 (post-septation). Also, lung microRNA expression screening 
was assessed in pups exposed to hyperoxia (85% O2) for 14 days. In total, 55 microRNAs 
were deregulated. Amongst the most up-regulated microRNAs were miR-15b and miR-497, 
both belong to miR-15 family. Target prediction analysis suggested that miR-15 family 
regulates Smad7 expression. Using a luciferase-based reporter assay, Smad7 was validated as 
a direct target of miR-15b suggesting an impact on TGF-β signaling during alveolarization. 
In vitro, overexpression of miR-15b and miR-497 down-regulated Smad7 expression and 
increased TGF-β responsiveness, as assessed by a p(CAGA)9 reporter assay in primary lung 
fibroblasts.  
In vivo silencing of miR-15b and miR-497 (by using LNA-antagomirs) restored 
alveolarization by ~50 % in developing lungs of mouse pups exposed to hyperoxia and was 
assessed by using a stereological approach. The mean linear intercept (MLI) was notably 
decreased in the hyperoxia treated group but the septal thickness (St) remained unchanged. 
These data reveal a causal role for the deregulated miR-15 family in arrested lung 
development associated with hyperoxia exposure. These data are also the first to report that 
microRNA inhibition, using LNA-antagomirs, is a viable interventional method to restore 
perturbed alveolarization.    
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7 Zusammenfassung   
  MicroRNAs sind die Schlüsselregulatoren der Organentwicklung. Deshalb wurde in 
den letzten Jahren viel auf dem Gebiet der microRNA Expression während der 
Embryonalentwicklung geforscht. Heutzutage gibt es noch keine Studien, welche die Rolle 
der microRNAs in der späten Lungenentwicklung, und besonders während der 
Alveolarisierung, postulieren. 
        Das microRNA-Screening der Lunge via microRNA microarray unter normoxischen 
Bedingungen ist an 4 Zeitpunkten durchgeführt worden, diese sind: P2.5 und P3.5, P5.5 und 
P14.5. Ebenso wurde mit Neonaten (Maus) verfahren, die für 14 Tage hyperoxischen 
Bedingungen ausgesetzt waren. 
Insgesamt sind 55 microRNAs dereguliert. Die am meisten hochregulierten microRNAs sind 
miR-15b und miR-497, beide gehören zur miR-15-Familie. Anhand der target prediction 
Analyse wurde angedeutet, dass die miR-15-Familie die Smad7-Expression reguliert. Mit 
dem luciferase-based reporter assay wurde bestätigt, dass miR-15b ein direktes Ziel von 
Smad7 ist und dies Auswirkungen auf die TGF-β Signalwirkung während der 
Alveolarisierung haben könnte. 
In vitro hatte die Überexpression von miR-15b und miR-497 eine schwächere Smad7-
Expression und erhöhte TGF-β Empfindlichkeit zur Folge, wie dies ebenso mit dem 
p(CAGA)9 reporter assay in primären Lungenfibroblasten bestätigt wurde. 
In vivo Silencing von miR-15b und miR-497 (mit LNA-antagomirs) führt zu einer 
Wiederherstellung der Alveolarisierung von ~50 % in Neonaten (Maus), die hyperoxischen 
Bedingungen ausgesetzt waren. Die Auswertung erfolgte hierbei mit einem 
Stereologieverfahren. Der mean linear intersept (MLI) ist in der hyperoxischen Gruppe 
erheblich reduziert wobei die Septumdicke unverändert bleibt. 
Diese Ergebnisse zeigen einen kausalen Zusammenhang zwischen deregulierten 
microRNAs der miR-15-Familie und gehemmter Lungenentwicklung unter hyperoxischen 
Bedingungen. Weiterhin zeigen diese Ergebnisse, dass Inhibierung der microRNA mit LNA-
antagomirs eine praktikable Therapie für gestörte Alveolarisierungsprozesse sein kann. 
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